As a counter-counter-point I've read most (~90%) of the papers that come out of trials registered at http://clinicaltrials.gov/ for all GLP-1 agonists, including ones that haven't been approved. The vast, vast, vast majority of secondary outcomes, for things like
- blood pressure
- lipids (HDL, LDL)
- insulin sensitivity
- blood glucose
- strokes
- cardiovascular events + deaths
- myocardial infarctions
- hemoglobin A1C,
- revascularization,
- etc, etc, etc
are literally all affected positively (to the benefit of the imaginary "mean" patient) in bulk.
Note though, that doesn't mean 100% of patients are have positive results, just that each of these are, in bulk, positive across the tested subjects when averaged together. There's little in the data to suggest that cases like your family member aren't happening or couldn't happen.
There's also evidence that GLP-1 agonists increase the rate of glucose use in the brain, accelerating learning rates. (The brain accounts for 2% of body weight but up to 25% of glucose consumption, it really is fueled by glucose)
- blood pressure
- lipids (HDL, LDL)
- insulin sensitivity
- blood glucose
- strokes
- cardiovascular events + deaths
- myocardial infarctions
- hemoglobin A1C,
- revascularization,
- etc, etc, etc
are literally all affected positively (to the benefit of the imaginary "mean" patient) in bulk.
Note though, that doesn't mean 100% of patients are have positive results, just that each of these are, in bulk, positive across the tested subjects when averaged together. There's little in the data to suggest that cases like your family member aren't happening or couldn't happen.
There's also evidence that GLP-1 agonists increase the rate of glucose use in the brain, accelerating learning rates. (The brain accounts for 2% of body weight but up to 25% of glucose consumption, it really is fueled by glucose)
https://clinicaltrials.gov/ct2/show/NCT00256256?term=stroke&...